Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort-Reference-Cited by-同舟云学术

Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort

Published:2021-05-18 Issue:6 Volume:19 Page:1436-1446
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Pasi K. John¹,Lissitchkov Toshko²,Mamonov Vasily³,Mant Tim⁴⁵,Timofeeva Margarita⁶,Bagot Catherine⁷,Chowdary Pratima⁸,Georgiev Pencho⁹,Gercheva‐Kyuchukova Liana¹⁰,Madigan Kate¹¹,Nguyen Huy¹¹,Yu Qifeng¹²,Mei Baisong¹²,Benson Craig C.¹²,Ragni Margaret V.¹³¹⁴

Affiliation:

1. Royal London Haemophilia Centre Barts and The London School of Medicine and Dentistry London UK

2. Clinic of Haematology National Specialized Hospital for Active Treatment of Haematologic Diseases Sofia Bulgaria

3. National Research Center for Hematology Moscow Russia

4. Iqvia Reading UK

5. Guy's and St Thomas' NHS Foundation Trust and Kings College London London UK

6. Federal State Budget Institution of Science “Kirov Scientific Research Institute of Hematology and Blood Transfusion of the Federal Medical‐Biological Agency" Kirov Russia

7. Department of Haematology Glasgow Royal Infirmary Glasgow UK

8. Katharine Dormandy Haemophilia and Thrombosis Centre Royal Free London NHS Foundation Trust London UK

9. University Multiprofile Hospital for Active Treatment “Sveti Georgi” and Medical University Plovdiv Plovdiv Bulgaria

10. Department of Hematology University Hospital of St. Marina Varna Bulgaria

11. Alnylam Pharmaceuticals Cambridge MA USA

12. Sanofi Cambridge MA USA

13. Department of Medicine University of Pittsburgh Pittsburgh PA USA

14. Hemophilia Center of Western Pennsylvania Pittsburgh PA USA

Funder

Sanofi Genzyme

Alnylam Pharmaceuticals

Publisher